State of Wisconsin Investment Board Acquires Shares of 22,058 Bioverativ Inc (BIVV)
State of Wisconsin Investment Board acquired a new stake in Bioverativ Inc (NASDAQ:BIVV) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 22,058 shares of the biotechnology company’s stock, valued at approximately $1,259,000.
Other institutional investors have also made changes to their positions in the company. Quotient Investors LLC purchased a new stake in shares of Bioverativ in the third quarter valued at approximately $420,000. Mutual of America Capital Management LLC purchased a new position in Bioverativ in the 3rd quarter worth approximately $5,062,000. Meeder Asset Management Inc. purchased a new position in Bioverativ in the 3rd quarter worth approximately $877,000. Rockefeller Financial Services Inc. purchased a new position in Bioverativ in the 3rd quarter worth approximately $1,480,000. Finally, State Treasurer State of Michigan purchased a new position in Bioverativ in the 3rd quarter worth approximately $2,323,000. Institutional investors and hedge funds own 96.95% of the company’s stock.
Bioverativ Inc (NASDAQ:BIVV) opened at $50.24 on Thursday. Bioverativ Inc has a 1 year low of $40.00 and a 1 year high of $64.41.
Bioverativ (NASDAQ:BIVV) last released its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.25. The business had revenue of $291.60 million during the quarter, compared to analysts’ expectations of $285.45 million. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. Bioverativ’s revenue for the quarter was up 27.2% on a year-over-year basis. equities research analysts forecast that Bioverativ Inc will post 2.45 earnings per share for the current fiscal year.
A number of research analysts have weighed in on BIVV shares. Zacks Investment Research lowered shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Jefferies Group LLC reissued a “buy” rating and issued a $70.00 target price (up from $67.00) on shares of Bioverativ in a research note on Wednesday, August 9th. Deutsche Bank AG set a $53.00 price target on shares of Bioverativ and gave the stock a “hold” rating in a report on Monday. Argus upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a report on Wednesday, September 20th. Finally, Cowen and Company restated a “buy” rating and set a $80.00 price target on shares of Bioverativ in a report on Friday, August 4th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $60.93.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.